Share ownership Legend Biotech Corporation

LEGN

US52490G1022

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 20:00:00 13/03/2026 GMT			5-day change	1st Jan Change
18.75 ^USD	-1.57%		-1.16%	-13.75%

03-11	Legend Biotech Shares Likely to Rebound in 2026 on Robust Fundamentals, RBC Says	MT
03-11	RBC Cuts Price Target on Legend Biotech to $62 From $66, Keeps Outperform Rating	MT

Share class: Legend Biotech Corporation

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	364,566,989	360,183,848 ( 98.8 %)	0	98.8 %

Major shareholders: Legend Biotech Corporation

Name	Equities	%	Valuation
Fidelity Management & Research Co. LLC 13.15 %	24,268,223	13.15 %	461 M $
Suvretta Capital Management LLC 3.581 %	6,608,629	3.581 %	126 M $
Westfield Capital Management Co. LP 3.34 %	6,164,677	3.34 %	117 M $
HHLR Advisors Ltd. (Cayman Islands) 3.242 %	5,984,550	3.242 %	114 M $
Deerfield Management Co. LP 3.214 %	5,932,000	3.214 %	113 M $
Deerfield Management Co. LP (Private Equity) 3.214 %	5,932,000	3.214 %	113 M $
BlackRock Institutional Trust Co. NA 1.809 %	3,339,101	1.809 %	63 M $
Point72 Asset Management LP 1.509 %	2,784,806	1.509 %	53 M $
Artisan Partners Holdings LP 1.268 %	2,341,074	1.268 %	44 M $
Goldman Sachs Asset Management LP 1.178 %	2,174,535	1.178 %	41 M $
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Equities	%	Valuation
GENSCRIPT BIOTECH CORPORATION 60.32 %	174,497,556	60.32 %	1 658 M $
Aquapoint LP 10.47 %	30,300,000	10.47 %	288 M $
Fang Liang Zhang 0.369 %	1,067,386	0.369 %	10 M $
Ying Huang 0.0741 %	214,364	0.0741 %	2 M $
Ye Wang 0.0583 %	168,642	0.0583 %	2 M $
Patrick Casey 0.0179 %	51,672	0.0179 %	490 884 $
Xiao Hui Ji 0.0178 %	51,415	0.0178 %	488 443 $
Corazon Sanders 0.0145 %	41,963	0.0145 %	398 649 $
Li Mao 0.00942 %	27,248	0.00942 %	258 856 $
Tomas Jan Heyman 0.005411 %	15,652	0.005411 %	148 694 $
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Genscript Biotech Corp.	94.54%
Institutional	47.43%
Other	19.64%
Individuals	0.9%
State Street Corp.	0.82%
Sumitomo Mitsui Trust Group, Inc.	0.09%
Schweizerische Nationalbank	0.09%
SEI Investments Co.	0.08%
Polar Capital Holdings Plc	0.03%
Manulife Financial Corp.	0.01%

Based on 1000 largest holdings

Geographical origin of shareholders

China	94.58%
United States	60.1%
Cayman Islands	3.31%
United Kingdom	1.44%
Individuals	0.9%
Hong Kong	0.75%
Switzerland	0.69%
Ireland	0.52%
Canada	0.34%
Luxembourg	0.29%
Japan	0.17%
Germany	0.11%
Australia	0.08%
Finland	0.06%
Sweden	0.06%
Austria	0.05%
Denmark	0.05%
France	0.04%
Norway	0.03%
Spain	0.02%
Singapore	0.02%
Belgium	0.01%
Italy	0.01%
Netherlands	0.01%

Based on 1000 largest holdings

Legend Biotech Corporation is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.

Employees

2,900

Sector

Biotechnology & Medical Research

More about the company